( Editorial: --> 8642 )
ZAGREB, Sept 7 (Hina) - Croatia's pharmaceutical giant Pliva on
Monday signed a licensing agreement with Receptron, Inc., a
California-based biotechnological company.
The agreement gives Pliva exclusive rights to the development of
medicines which act similarly to endogenous trombopoetine (TPO),
but have additional advantages as well.
In line with the agreement, Pliva will assist Receptron in
research, pay out exclusive rights and royalties from future
sales.
TPO is a growth agent which stimulates the production of blood
vessels.
It should also replace transfusions which are expensive and high-
risk due to possibilities of HIV and hepatitis infections.
It is expected the TPO product's market potential will be in excess
of US$500 million.
(hina) ha jn/sp
071640 MET sep 98
Počela izgradnja rotora Pavlovac na frekventnom raskrižju u Rijeci
Gospodarstvo - ukratko do 17,30 sati
Tjedna najava događaja - Hrvatska - od 1. do 7. veljače
Tjedna najava događaja - kultura - od 1. do 7. veljače
OIF: Tek jedan gubitnik
Gavi ostaje u Barceloni do 2030.
Najava događaja - Hrvatska - za subotu 1. veljače
Mađar i Mađarica krali crkvene oluke po Slavoniji
ZSE: Crobexi porasli četvrti dan, u fokusu Valamar Riviera
Najava događaja - kultura - za subotu, 1. veljače